- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
7
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
7 companies
CanSino Biologics
Market Cap: HK$9.7b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$23.28
7D
-0.4%
1Y
-46.8%
Biocytogen Pharmaceuticals (Beijing)
Market Cap: HK$47.0b
A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.
2315
HK$50.15
7D
-3.7%
1Y
97.1%
Akeso
Market Cap: HK$86.5b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$93.95
7D
-5.6%
1Y
-39.9%
Innovent Biologics
Market Cap: HK$150.9b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
1801
HK$86.70
7D
-3.6%
1Y
-6.8%
Frontage Holdings
Market Cap: HK$2.4b
Provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
1521
HK$1.17
7D
2.6%
1Y
-22.0%
InSilico Medicine Cayman TopCo
Market Cap: HK$26.2b
Engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms.
3696
HK$45.70
7D
-2.9%
1Y
n/a
WuXi XDC Cayman
Market Cap: HK$65.6b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$51.80
7D
-6.8%
1Y
-6.7%